| Literature DB >> 35458438 |
Dragica Damnjanović1, Xabier Vázquez-Campos2, Lisa Elliott3, Mark Willcox4, Wallace J Bridge1.
Abstract
Recent acknowledgment that multidrug resistant Stenotrophomonas maltophilia strains can cause severe infections has led to increasing global interest in addressing its pathogenicity. While being primarily associated with hospital-acquired respiratory tract infections, this bacterial species is also relevant to ophthalmology, particularly to contact lens-related diseases. In the current study, the capacity of Stenotrophomonas phage vB_SmaM_Ps15 to infect ocular S. maltophilia strains was investigated to explore its future potential as a phage therapeutic. The phage proved to be lytic to a range of clinical isolates collected in Australia from eye swabs, contact lenses and contact lens cases that had previously shown to be resistant to several antibiotics and multipurpose contact lenses disinfectant solutions. Morphological analysis by transmission electron microscopy placed the phage into the Myoviridae family. Its genome size was 161,350 bp with a G + C content of 54.2%, containing 276 putative protein-encoding genes and 24 tRNAs. A detailed comparative genomic analysis positioned vB_SmaM_Ps15 as a new species of the Menderavirus genus, which currently contains six very similar globally distributed members. It was confirmed as a virulent phage, free of known lysogenic and pathogenicity determinants, which supports its potential use for the treatment of S. maltophilia eye infections.Entities:
Keywords: Menderavirus; Stenotrophomonas maltophilia; bacteriophage
Mesh:
Year: 2022 PMID: 35458438 PMCID: PMC9025141 DOI: 10.3390/v14040709
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
The S. maltophilia strains used for susceptibility testing with phage Ps15.
| Strain Name | Isolation Date | Isolation Source | Keratitis-Associated (Y/N) | Antibiotic Resistance * | MPDS Resistance # |
|---|---|---|---|---|---|
| Xmal2 | 4 February 1994 | Eye swab | N | azt (I), imi (R), tob (R), chl (I) | AQ, RH, MC |
| Xmal7 | 23 September 1994 | Eye swab | Y | azt (I), imi (R), chl (I) | AQ, RH, MC |
| Xmal10 | 15 December 1994 | Eye swab | Y | azt (I), imi (R), chl (I) | AQ, RH, EM, MC |
| Xmal12 | 12 October 1995 | Eye swab | Y | ND | ND |
| Xmal15 | 19 March 1998 | Contact lens | Y | azt (I), imi (R), chl (R) | AQ, RH, MC |
| Xmal21 | 2 April 2001 | Contact lens | Y | cip (R), ofl (I), imi (R), gen (R), tob (R), chl (I) | AQ, RH |
| Smal1 | 12 December 2005 | Cystic fibrosis swab | N | azt (I), imi (R), chl (I) | AQ, RH, MC |
| Smal2 | 25 May 1998 | Contact lens case | N | cip (I), imi (R), gen (I), chl (I) | AQ, RH, MC |
| Smal6 | 9 September 2010 | Contact lens case | Y | azt (R), cep (R), imi (R), chl (I) | AQ, RH, MC |
| Smal7 | 11 November 2010 | Contact lens case | N | azt (R), imi (R) | AQ, RH |
| Smal8 | 26 November 2010 | Contact lens case | N | imi (R), chl (I) | AQ, RH |
| Smal9 | 1 February 2011 | Contact lens case | N | imi (R) | AQ, RH, MC |
| Smal10 | 14 February 2011 | Contact lens case | N | imi (R) | AQ, RH, MC |
| Smal11 | 9 March 2011 | Contact lens case | N | azt (I), imi (R), pmb (R) | AQ, RH, EM, MC |
| Smal12 | 24 March 2011 | Contact lens case | Y | imi (R) | AQ, RH, MC |
| Smal13 | 1 April 2011 | Contact lens case | N | azt (R), cep (R), imi (R), | AQ, RH, MC |
| Smal14 | 5 April 2011 | Contact lens case | N | azt (I), imi (R), chl (R), | AQ, RH |
| Smal15 | 7 April 2011 | Contact lens case | N | azt (R), imi (R), chl (I) | AQ, RH, MC |
| Smal16 | 17 May 2011 | Contact lens case | N | azt (I), imi (R), | AQ, RH, MC |
| Smal17 | 6 June 2011 | Contact lens case | N | imi (R) | AQ, RH, MC |
| Smal18 | 1 July 2011 | Contact lens case | N | azt (R), cep (I), imi (R), | BT, AQ, RH, MC |
| Smal19 | 8 July 2011 | Contact lens case | N | azt (I), cep (R), imi (R) | BT, AQ, RH, MC |
| Smal20 | 5 July 2011 | Contact lens case | N | azt (R), cep (I), imi (R), tic (R), chl (I) | AQ, RH, MC |
| Smal21 | February 2012 | Contact lens case | N | ND | ND |
*, tested against; ciprofloxacin (cip), gatifloxacin (gat), levofloxacin (lev), moxifloxacin (mox), ofloxacin (ofl), aztreonam (azt), ceftazidime (cez), cefepime (cep), imipenem (Imi), ticarcillin (tic), gentamicin (gen), tobramycin (tob), tigecycline (tig), trimethoprim/sulfamethozole (cotrimoxazole; cot), chloramphenicol (chl), polymyxin B (pmb); I = intermediate resistance, R = resistant, ND = not determined. #, resistance to MPDS defined as being growth in >10% v/v multipurpose disinfectant solutions (MPDS) [32]; RevitaLens (RL), ReNu fresh (RF), Biotrue (BT), Aquify (AQ), RepleniSH (RH), EverMoist (EM), MeniCare (MC).
Figure 1Ps15 plaque morphology on: (a) TSA with calcium chloride; (b) TSA without calcium chloride (the arrow points to a halo); (c) 10 µL spot on S. maltophilia Smal2; (d) 10 µL spot on S. maltophilia Smal17.
Efficiency of plating (EOP) of phage Ps15 on different bacterial hosts expressed as the ratio of the phage titre of the tested strains and the titre of the propagating host strain (2.1 × 108 PFU/mL).
| Strain Name | Relative Efficiency of Plating | Single Plaque Description |
|---|---|---|
| Smal15 | 1.9 | clear |
| Smal16 | 1.8 | clear |
| Smal20 | 1.67 | clear |
| Xmal2 | 1.17 | clear |
| Smal2 | 1.08 | turbid |
| Xmal10 | 1 | clear |
| AP143S | 1 | clear |
| Smal12 | 0.91 | clear |
| Smal6 | 0.82 | clear |
| Smal11 | 0.8 | clear |
| Smal21 | 0.76 | clear |
| Xmal7 | 0.75 | turbid |
| Smal14 | 0.42 | turbid |
| Smal17 | 0.38 | clear |
| Smal8 | 0.28 | clear |
| Smal9 | 0.23 | clear |
| Smal10 | 0.11 | clear |
| Xmal15 | 0.06 | clear |
| Smal1 | 0.04 | clear |
| Smal7 * | 0.04 | turbid |
| Smal13 * | 0.03 | turbid |
| Smal18 | No single plaques (plaque spots at 105–108 PFU/mL) | - |
| Smal19 | No single plaques (plaque spots at 105–108 PFU/mL) | - |
| Xmal12 | - | - |
| Xmal21 | - | - |
| PAO1 | - | - |
* Smal7 and Smal13 produced no lysis in the initial test and single plaques at the level 105 PFU/mL in the repeated test. ‘-’—no plaque.
Figure 2Transmission electron micrographs of the Ps15 phage particles stained with 2% (w/v) uranyl acetate displaying the Myoviridae morphotype. Magnification × 60 K. The extensions from a tail (b) and a capsid (c) are indicated by arrows. Note the specimens with straight short fibres (a) and their transformation into globular-looking forms (b). Scale bars are included for each image.
Figure 3Electron micrographs of 2% (w/v) uranyl acetate negatively stained filamentous structures in the original Ps15 phage lysate. Acceleration voltages: (a) 15 kV; (b) 20 kV; (c) 80 kV and (d) 100 kV. Scale bars are included in each figure.
Figure 4(a) One step growth curve depicting the infection of S. maltophilia AP143S by phage Ps15 at a MOI of 0.001. (b) Phage adsorption assay. Error bars indicate the standard deviation of triplicates.
Figure 5Kill curves of phage Ps15 at different MOIs showing progressive lysis of the host S. maltophilia AP143S in TSB at 37 °C. Growth inhibition was assessed against the non-infected bacterial culture used as a control. The plotted values are averaged from six replicate OD595 measurements. Error bars indicate the standard deviation of the replicates.
Figure 6Lysis of S. maltophilia AP143S by Ps15 (MOI 0.1) in tryptone soy broth at 37 °C, with (10 mM) and without the addition of calcium chloride ions. Error bars indicate the standard deviation of triplicates.
General characteristics of Ps15 and other known Menderavirus genomes. Values based on the annotations performed in this study unless otherwise stated.
| Phage Name | Size (bp) | GC% | Proteins a | Coding Density | tRNAs ab | Genome Similarity/Query Cover (%) c | Average Amino Acid Identity (%) d | Shared Proteins (%) |
|---|---|---|---|---|---|---|---|---|
| Ps15 | 161,350 | 54.2 | 275 | 93.86 | 24 | 100.0/100 | 100 | 276 (100) |
| BUCT608 | 160,122 | 54.2 | 270 (266) | 94.15 | 24 (20) | 98.62/92 | 93.90 | 221 (81.85) |
| IME-SM1 | 159,514 | 54.1 | 267 (202) | 92.88 | 24 (20) | 98.50/91 | 93.63 | 210 (78.65) |
| Marzo | 159,384 | 54.0 | 262 (268) | 93.65 | 24 (23) | 97.49/90.5 | 91.75 | 213 (81.30) |
| Mendera | 159,961 | 54.0 | 272 (286) | 94.05 | 24 (23) | 98.07/89.5 | 91.13 | 207 (76.10) |
| Moby | 159,365 | 54.1 | 268 (271) | 94.02 | 24 (23) | 94.73/91.5 | 91.98 | 215 (80.22) |
| YB07 | 159,862 | 54.1 | 269 (257) | 93.85 | 24 (0) | 98.45/90.5 | 93.47 | 220 (81.78) |
a: values from NCBI’s public genome annotations in parenthesis. b: includes predicted pseudo-genes and tRNAs of indetermined specificity. c: based on genome vs. genome with blastn. The values indicate the average of reciprocal hits. d: see Table S4 for full analysis.
Figure 7Genome map of Ps15. Outer line graphs depict the GC content and GC skew of the genome. The genome features are coloured based on the gene type, function of the encoded protein, or genomic feature. Inner coloured rings show high identity matches of other Menderavirus genomes against Ps15. The red box marks an area of tRNAs with a magnified image in the top left corner showing their position on the genome. Image generated with GView [57].
Figure 8Upset plot depicting the number of shared and unique gene clusters in the Menderavirus genomes. Note that after the core genome (188 gene clusters), the Ps15 singletons (51) and the genes only absent in Ps15 (28) constitute the largest intersections.
Figure 9Detailed pairwise comparison of the long cluster of genes encoded in the reverse strand of Menderavirus. The view is extended to the first conserved genes in the positive strand at each side of the region. The strains are ordered based on Figure 8C. Gene links are shaded based on identity (minimum 30%). Image generated with Clinker v0.0.21 [72].
Figure 10Phylogenetic trees showing the placement of Ps15 in respect to other phages. Phylogenies are based on the major capsid protein (A), the large terminase subunit (B), and on the partitioned phylogenomic analysis with 188 core proteins (C). Tip colours indicate the phylum of the host. Trees were rooted using non-reversible substitution models.